Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shilpak Chatterjee

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Cells|August 11, 2023
Intratumoral PD1<sup>+</sup>CD38<sup>+</sup>Tim3<sup>+</sup> CD8<sup>+</sup> T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder CancerDebashree Basak, Soumya Mondal, Swadeep Kumar Srivastava, et al.
The Journal of Investigative Dermatology|January 31, 2015
CCL22 to Activate Treg Migration and Suppress Depigmentation in VitiligoJonathan M Eby, Hee-Kap Kang, Sean T Tully, et al.
BMC Cancer|November 17, 2006
A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivoAnanda Mookerjee, Jayati Mookerjee Basu, Surajit Majumder, et al.
Iscience|August 29, 2022
Quantitative increase in T regulatory cells enhances bone remodeling in <i>osteogenesis imperfecta</i>In-Hong Kang, Uday K Baliga, Shilpak Chatterjee, et al.
Gut Pathogens|May 10, 2023
Association of gut microbial dysbiosis with disease severity, response to therapy and disease outcomes in Indian patients with COVID-19Daizee Talukdar, Purbita Bandopadhyay, Yogiraj Ray, et al.
Cancer Research|September 11, 2014
Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumorsShilpak Chatterjee, Krishnamurthy Thyagarajan, Pravin Kesarwani, et al.
The Journal of Investigative Dermatology|December 25, 2013
A quantitative increase in regulatory T cells controls development of vitiligoShilpak Chatterjee, Jonathan M Eby, Amir A Al-Khami, et al.
The Journal of Clinical Investigation|May 22, 2018
PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunityAnusara Daenthanasanmak, Yongxia Wu, Supinya Iamsawat, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2024
CD38-RyR2 axis-mediated signaling impedes CD8<sup>+</sup> T cell response to anti-PD1 therapy in cancerAnwesha Kar, Puspendu Ghosh, Anupam Gautam, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2022
Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19Deblina Raychaudhuri, Purbita Bandopadhyay, Ranit D'Rozario, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Cells|August 11, 2023
Intratumoral PD1<sup>+</sup>CD38<sup>+</sup>Tim3<sup>+</sup> CD8<sup>+</sup> T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder CancerDebashree Basak, Soumya Mondal, Swadeep Kumar Srivastava, et al.
The Journal of Investigative Dermatology|January 31, 2015
CCL22 to Activate Treg Migration and Suppress Depigmentation in VitiligoJonathan M Eby, Hee-Kap Kang, Sean T Tully, et al.
BMC Cancer|November 17, 2006
A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivoAnanda Mookerjee, Jayati Mookerjee Basu, Surajit Majumder, et al.
Iscience|August 29, 2022
Quantitative increase in T regulatory cells enhances bone remodeling in <i>osteogenesis imperfecta</i>In-Hong Kang, Uday K Baliga, Shilpak Chatterjee, et al.
Gut Pathogens|May 10, 2023
Association of gut microbial dysbiosis with disease severity, response to therapy and disease outcomes in Indian patients with COVID-19Daizee Talukdar, Purbita Bandopadhyay, Yogiraj Ray, et al.
Cancer Research|September 11, 2014
Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumorsShilpak Chatterjee, Krishnamurthy Thyagarajan, Pravin Kesarwani, et al.
The Journal of Investigative Dermatology|December 25, 2013
A quantitative increase in regulatory T cells controls development of vitiligoShilpak Chatterjee, Jonathan M Eby, Amir A Al-Khami, et al.
The Journal of Clinical Investigation|May 22, 2018
PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunityAnusara Daenthanasanmak, Yongxia Wu, Supinya Iamsawat, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2024
CD38-RyR2 axis-mediated signaling impedes CD8<sup>+</sup> T cell response to anti-PD1 therapy in cancerAnwesha Kar, Puspendu Ghosh, Anupam Gautam, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2022
Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19Deblina Raychaudhuri, Purbita Bandopadhyay, Ranit D'Rozario, et al.
Pageof 5